Long-term treatment with the dopamine agonist CV 205–502 of patients with a clinically non-functioning, gonadotroph, or α-subunit secreting pituitary adenoma

摘要: Objective We aimed to assess the effects of prolonged treatment with dopamine agonist CV 205-502 on tumour volume, visual field defects, and serum gonadotrophin alpha-subunit concentrations in patients gonadotroph, secreting, or clinically non-functioning pituitary adenomas. Design The were treated a final daily dose 300 micrograms for at least 1 year. seen 2 3-week intervals during first 3 months treatment, thereafter every months. Computerized tomography Goldmann perimetry performed before follow-up. Blood samples drawn each out-patient visit. Patients One patient two adenomas studied. Results showed shrinkage one patient. In other an improvement defects was observed. four patients, significant decrease FSH and/or occurred within treatment. remaining patient, found after more than Conclusions non-functioning, secreting tumours, long-term decreases concentrations. This decreased secretory activity from may be accompanied by computerized tomography. Therefore, useful who cannot operated upon.